UNLOCKING THE SOCIOECONOMIC BENEFITS OF ADULT RESPIRATORY VACCINATION IN MEXICO: THE CASE FOR BROADER PREVENTION STRATEGIES
Author(s)
SooChin Yen, MPharm1, Matthew William Napier, MSc1, Ellie Tunnicliffe, BSc1, Simon Brassel, BSc, MSc1, Tianyan Hu, PhD2, Carlos Fernando Mendoza, PhD3, Liping Huang, MA, MS, MD4, Diana Mendes, PhD5, Veronica Judith Guajardo, MSc6, Andrea Del Bosque, MD6, Lotte Steuten, MSc, PhD1.
1Office of Health Economics (OHE), London, United Kingdom, 2Pfizer, New York, NY, USA, 3Pfizer Inc, Mexico City, Mexico, 4Pfizer Inc, Collegeville, PA, USA, 5Pfizer Ltd., Tadworth, United Kingdom, 6Pfizer, Mexico City, Mexico.
1Office of Health Economics (OHE), London, United Kingdom, 2Pfizer, New York, NY, USA, 3Pfizer Inc, Mexico City, Mexico, 4Pfizer Inc, Collegeville, PA, USA, 5Pfizer Ltd., Tadworth, United Kingdom, 6Pfizer, Mexico City, Mexico.
OBJECTIVES: Vaccine-preventable respiratory illnesses impose a significant public health and economic burden in Mexico. The National Immunization Program (NIP) currently includes vaccines for COVID-19, influenza, and pneumococcal disease (PD) for adults based on age or risk factors. This study estimates the socioeconomic value of existing adult respiratory vaccination programs and explores hypothetical scenarios, including the recommendations of respiratory syncytial virus (RSV) vaccination, and improved coverage rates.
METHODS: We conducted a benefit-cost analysis (BCA) from a societal perspective, using four disease-specific multi-cohort models. The models simulated annual vaccinations for COVID-19 and influenza and single-dose vaccinations for RSV and PD over the remaining lifetime of the population, compared with no vaccination. Outcomes were monetized across three domains: mortality risk reduction, morbidity risk reduction, and changes in time use. Mortality benefits were valued either age-agnostic, based on the value of a statistical life (VSL), or, age-dependent, using the value of a statistical life year (VSLY) approach. Morbidity risk reductions were valued using a cost-of-illness approach. All monetized benefits were aggregated to generate net benefits (NBs), and benefit-cost ratios (BCRs) at 1-, 7-,15-year and lifetime horizons.
RESULTS: The lifetime BCR of the current age-based respiratory vaccination program ranged from 2.7 to 11.8 MXN per 1 MXN invested (VSLY-VSL, same below), corresponding to NBs of 35-217 billion MXN. Expanding eligibility to risk groups and adding RSV vaccination increased NBs by 95%-78%, hospitalizations prevented by 288%, and deaths averted by 106%. These changes, combined with aspirational vaccine coverage rates of 75% across all programs, increase NBs by 159%-152%.
CONCLUSIONS: Adult respiratory vaccination programs in Mexico deliver substantial societal socioeconomic returns. Additionally, incorporating RSV vaccination into the NIP and improving coverage rates further grow these benefits, providing evidence to support continued public investment to broaden the value of vaccination programs.
METHODS: We conducted a benefit-cost analysis (BCA) from a societal perspective, using four disease-specific multi-cohort models. The models simulated annual vaccinations for COVID-19 and influenza and single-dose vaccinations for RSV and PD over the remaining lifetime of the population, compared with no vaccination. Outcomes were monetized across three domains: mortality risk reduction, morbidity risk reduction, and changes in time use. Mortality benefits were valued either age-agnostic, based on the value of a statistical life (VSL), or, age-dependent, using the value of a statistical life year (VSLY) approach. Morbidity risk reductions were valued using a cost-of-illness approach. All monetized benefits were aggregated to generate net benefits (NBs), and benefit-cost ratios (BCRs) at 1-, 7-,15-year and lifetime horizons.
RESULTS: The lifetime BCR of the current age-based respiratory vaccination program ranged from 2.7 to 11.8 MXN per 1 MXN invested (VSLY-VSL, same below), corresponding to NBs of 35-217 billion MXN. Expanding eligibility to risk groups and adding RSV vaccination increased NBs by 95%-78%, hospitalizations prevented by 288%, and deaths averted by 106%. These changes, combined with aspirational vaccine coverage rates of 75% across all programs, increase NBs by 159%-152%.
CONCLUSIONS: Adult respiratory vaccination programs in Mexico deliver substantial societal socioeconomic returns. Additionally, incorporating RSV vaccination into the NIP and improving coverage rates further grow these benefits, providing evidence to support continued public investment to broaden the value of vaccination programs.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE91
Topic
Economic Evaluation
Disease
STA: Vaccines